Green Cash Money

Weekend Technical Guidance - Can The Late Day Squeezes Continue? June 1st-5th, 2009

AGORACOM Small Cap TV - May 29, 2009

May 29, 2009 Mid-Day Stock Indexes Review

Market Technical Guidance - Financials And Tech Weak…But Dollar Keeping The Markets Up 05/29/09

Biovest International, Inc., a biotechnology company, develops therapeutic anti-cancer vaccine for the treatment of low-grade Follicular Lymphoma in the United States. It develops BiovaxID, a Phase III clinical trial product, which is an injectable patient-specific vaccine to treat the follicular form of non-Hodgkin’s lymphoma. The company develops, manufactures, and markets cell culture systems, equipment, and consumable parts to pharmaceutical, diagnostic, and biotechnology companies, as well as to research institutions worldwide. Biovest International also produces mammalian and insect cells, monoclonal antibodies, recombinant and secreted proteins, and other cell culture products using hollow fiber perfusion. It is also developing an automated cell culture instrument, AutovaxID that enables production of personalized cell-based treatments. In addition, the company sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. Further, Biovest International engages in the production and contract manufacture of biologic drugs and cell production for research institutions. Its customers include biopharmaceutical and biotech companies, medical schools, universities, research facilities, hospitals, and public and private laboratories. The company was incorporated in 1981 as Endotronics, Inc. and changed its name to Cellex Biosciences, Inc. in 1993. Further, it changed its name to Biovest International, Inc. in 2001. The company is based in Worcester, Massachusetts. Biovest International, Inc. is a subsidiary of Accentia Biopharmaceuticals, Inc. On November 10, 2008, Biovest International Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Middle District of Florida, Tampa, in joint administration with Accentia Biopharmaceuticals, Inc.

BVTI at 9:51 AM 5/29/2009:  Running up briskly

BrandPartners Group, Inc., through its subsidiaries, provides integrated products and services to the financial and non-financial retailers in the United States and Canada. Its products and services include brand translations; branch network analysis and branch strategic planning; strategic market intelligence; environmental design, construction, and project management services; point-of-sale communications, and branch environment sales training and marketing programs; and space planning and contract furniture solutions. The company also provides retail communications products and services, including interior and exterior merchandising, digital networks and content management, logistics, distribution, and inventory management. BrandPartners Group offers its products and services to retail banking organizations, bank holding companies, and thrifts; regional and community banks; credit unions; non-bank financial services companies, such as mutual fund, asset management, insurance and mortgage, and tax services companies, as well as brokerage houses; and other retail industries and service organizations. It has a strategic alliance with Rockefeller Consulting Group/Insight Capitalists. The company was formerly known as Financial Performance Corporation and changed its name to BrandPartners Group, Inc. in 2001. BrandPartners Group was founded in 1984 and is based in Rochester, New Hampshire.

BPTR at 9:41 AM 5/29/2009:  Crossed daily highs resistance

BIOMAG Corporation, through its subsidiary, Bio-Spectrum Technologies, Inc., designs, patents, and markets diagnostic equipment and immunoassays. It owns High Throughput Screening-Magnetic Testing Platform, a patented diagnostic system that provides confirmatory and viral load diagnostics. The company was founded in 1997 and is based in Orangevale, California.

BMGP at 9:34 AM 5/29/2009:  Trading 54% above VWAP